true

BD MAX™

Redefine staff productivity with a fully integrated, automated molecular platform

BD MAX - Header image
Loading

Performance, efficiency, and versatility at your fingertips

 

The BD MAX™ System is designed to help address today’s challenges, while preparing your laboratory for tomorrow’s possibilities with a broad and expanding suite of assays, while also providing open-system flexibility for users to design and run their own assays.1

The BD MAX™ System is a fully-integrated, automated platform that performs nucleic acid extraction and real-time PCR providing results for up to 24 samples across multiple syndromes in approximately 3 hours*

*Assay times may vary

Click on the category to explore how our products can help:

Enteric Solutions

Champion a targeted, syndromic testing approach

The BD MAX™ Enteric Solutions offer targeted syndromic panels that provide timely and accurate detection of the most common bacterial, viral and parasitic pathogens responsible for infectious diarrhea.2,3,4

Acute infectious gastroenteritis (AGE) challenges the healthcare system. There is a high incidence of AGE in the U.S. and it is a common reason for outpatient visits and hospitalizations, with approximately 179 million cases per year5 and 128,000 hospitalizations per year.6

Conventional methods used to detect agents of AGE infections such as culture, microscopy, and immunoassays come with disadvantages:

  • Culture, isolation, and identification can be laborious and time consuming7
  • Culture methods can take days to provide a result8
  • Culture, microscopy, and immunoassays can have poor sensitivity compared to PCR based assays9,10,11

 

This can lead to less effective clinical decision-making and result in:12

  • Inappropriate antibiotic treatment
  • Unnecessary patient isolation
  • Extended hospital stays

The system provides highly sensitive and specific results through real-time PCR technology, and consistent results through standardized workflow and protocols.

  • Salmonella spp.
  • Campylobacter spp. (jejuni and coli)
  • Shigella spp./Enteroinvasive E. coli (EIEC)
  • Shiga toxin 1 & 2 (E. coli [STEC], Shigella dysenteriae)


Catalog number: 442963

Extends testing coverage to lower-prevalence bacterial pathogens.16

  • Plesiomonas shigelloides
  • Vibrio spp. (V. vulnificus, V. parahaemolyticus, and V. cholerae)
  • Enterotoxigenic E. coli (ETEC)
  • Yersinia enterocolitica


Catalog number: 443812

Detects 3 commonly isolated and highly pathogenic parasites that cause gastroenteritis.17

  • Giardia lamblia
  • Cryptosporidium (C. hominis and C. parvum)
  • Entamoeba histolytica


Catalog number: 442960

Broad coverage of key viral pathogens – Norovirus, Rotavirus, Adenovirus (40/41), Sapovirus, and Human Astrovirus.18

  • Norovirus GI/GII
  • Rotavirus A
  • Adenovirus F40/41
  • Sapovirus (geno-groups I, II, IV, V)
  • Human Astrovirus (hAstro)


Catalog number: 443985

Healthcare Associated Infections (HAIs)

Set higher standards in the fight against HAIs

While progress has been made in the fight against healthcare-associated infections (HAIs), they are still among the leading threats to patient safety. HAIs affect one out of every 31 hospital patients at any one time. Over 1,000,000 HAIs occur across the U.S. healthcare system every year, leading to the loss of tens of thousands of lives and adding billions of dollars to healthcare costs.19

By combining early and accurate detection of HAIs with appropriate infection control interventions and patient treatment, we can prevent transmission, improve patient management and reduce the financial burden on healthcare systems.20

Explore the BD MAX™ HAI Portfolio

BD has deep history in microbiology—from plated media to molecular diagnostics—demonstrating our unique strength in helping hospitals manage the spread of infections.

BD offers a comprehensive suite of molecular solutions designed to detect healthcare-associated infections on the BD MAX™ System. Molecular testing is highly sensitive and provides a faster result compared to culture methods, which can aid in more effective infection control measures.21,22

The BD MAX System™ delivers automated extraction, amplification and detection of the most common HAIs, with up to 24 patient results in approximately 3 hours.

The BD MAX™ Cdiff assay is a test for the detection of the Clostridioides difficile toxin B gene (tcdB) in liquid or soft stool from patients suspected of having Clostridioides difficile infection (CDI). The assay provides a highly accurate result in an actionable timeframe and requires limited hands-on time as compared to traditional methods.23

  • Clostridium difficile toxin B gene (tcdB)

 

Catalog number: 443418

The BD MAX™ MRSA XT Panel is a screening test for nasal carriage of MRSA aiding in transmission prevention and infection control. The assay provides comprehensive coverage including detection of 11 MREJ genotypes representing most of mecA and mecC harboring MRSA strains in addition to mecA and mecC gene drop-out mutants.

  • Methicillin-resistant Staphylococcus aureus (MRSA)


Catalog number: 443461

The BD MAX™ StaphSR Panel is a pre-surgical screening test for nasal carriage of Staphylococcus aureus or MRSA aiding in transmission prevention and infection control. The assay offers the same level of comprehensive coverage as the BD MAXTM MRSA XT assay, including detection of 11 MREJ genotypes representing most of mecA and mecC harboring MRSA strains in addition to mecA and mecC gene drop-out mutants.24

  • Methicillin-resistant Staphylococcus aureus (MRSA)
  • Staphylococcus aureus (SA)


Catalog number: 443419

The BD MAX™ CPO assay is intended as an aid to infection control in the detection of carbapenem-non-susceptible bacteria that colonize patients in healthcare settings. The assay is designed for the detection and differentiation of the carbapenemase genes blaKPC, blaNDM, blaVIM/blaIMP and blaOXA-48, that are associated with carbapenem non-susceptibility in gram-negative bacteria.25

  • KPC (Klebsiella pneumoniae carbapenemase)
  • NDM (New Delhi metallo-β-lactamase)
  • OXA-48 (Oxacillinase-48 and OXA-48 like variants)
  • VIM (Verona integron–encoded metallo-β-lactamase)/IMP (Imipenemase)


Catalog number: 445262

We proudly offer the BD MAX™ Club, providing an on-demand resource library to optimize molecular practices with tutorials, scientific studies, and more!

Women's Health

Elevate the standard of care

Vaginitis/Vaginosis, STIs, and antepartum

Clinicians and laboratories are faced with increasing challenges in managing workload and patient needs when it comes to reproductive health. Staggering costs to the U.S. healthcare system caused by the growing number of new infections demand action in the way we test for sexually-transmitted infections (STIs).26 For vaginal infections, traditional diagnostics leave up to 40% of women with vaginitis undiagnosed after an initial clinical visit.27 Visit our women’s health solutions site to learn more about the BD Women’s Health portfolio of products.

Explore the BD MAX™ Women’s Health and STI Portfolio

The BD MAX™ Vaginal Panel is the first FDA market-authorized, microbiome-based, polymerase chain reaction (PCR) assay that directly detects the 3 most common infectious causes of vaginitis: Bacterial vaginosis, vulvovaginal candidiasis and trichomoniasis.28

With the BD MAX™ Vaginal Panel, you can maximize efficiency with 1 collection, 1 test for the 3 most common infectious causes of vaginitis. This assay separately reports Candida krusei and Candida glabrata, which may assist clinicians in choosing the appropriate antimicrobial therapy for their patients.29

The BD MAX™ Vaginal Panel is the first FDA market-authorized, microbiome-based, polymerase chain reaction (PCR) assay that directly detects the 3 most common infectious causes of vaginitis: Bacterial vaginosis, vulvovaginal candidiasis and trichomoniasis.28

With the BD MAX™ Vaginal Panel, you can maximize efficiency with 1 collection, 1 test for the 3 most common infectious causes of vaginitis. This assay separately reports Candida krusei and Candida glabrata, which may assist clinicians in choosing the appropriate antimicrobial therapy for their patients.29

  • Bacterial vaginosis (combination of markers)
  • Candida group (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis)
  • C. krusei
  • C. glabrata
  • Trichomonas vaginalis


Catalog number: 443712

The BD MAX™ CTGCTV2 Assay is designed to detect the 3 most prevalent non-viral sexually transmitted infections - Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC), and Trichomonas vaginalis (TV) - in a single assay. With BD MAX™ CTGCTV2 assay you can provide quality patient care and support clinical decision accuracy and patient management.30

  • Group B Streptococcus


Catalog number: 441772

The BD MAX™ GBS assay is a fully-automated, real-time PCR method for the detection of GBS from enriched culture. It simplifies detection of GBS colonization in antepartum pregnant women, and rapidly identifies Group B Streptococcus after an overnight Lim Broth enrichment.31

  • Chlamydia trachomatis
  • Neisseria gonorrhoeae
  • Trichomonas vaginalis


Catalog number: 443904

Respiratory

Clinical differentiation that matters

SARS-CoV-2, Influenza (flu), and respiratory syncytial virus (RSV) are 3 different viral respiratory infections that often present with overlapping signs and symptoms. Ensuring accurate diagnosis and treatment for these conditions can be extremely difficult without access to testing.32,33

Testing can help better ensure accurate diagnosis and rule out possibilities of co-infection. It may also reduce community transmission, improve disease surveillance efforts, and better inform patient treatment and management decisions. This is especially critical for patients at higher-risk of severe infection such as the elderly, young children, and those with co-infections, or certain pre-existing medical conditions.30,31,34,35

With the BD Respiratory Viral Panel for BD MAX™ System, you can simultaneously detect and differentiate SARS-CoV-2, influenza A, influenza B and/or RSV from one sample. 36

  • Identify co-occurring respiratory infections37
  • Provide clinically meaningful results that inform patient management strategies38,39
  • Increase testing capacity and help eliminate the need for multiple tests or doctor visits40

 

  • Flu A (M1 gene)
  • Flu B (M1 and HA genes)
  • RSV (N and M genes)
  • SARS-CoV-2 (N1 and N2 genes)

 

Catalog number: 445373

The BD SARS-CoV-2 Reagents for BD MAX™ System is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal, anterior nasal, mid-turbinate, and oropharyngeal swab specimens as well as nasopharyngeal wash/aspirate or nasal aspirate specimens obtained from any individuals, including individuals without symptoms or other reasons to suspect COVID-19.41

  • SARS-CoV-2 (N1& N2)

 

Catalog number: 44500301


Disclaimer for the BD SARs-CoV-2 Reagents for BD MAX System: This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories; This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

Open System Reagents

Achieve MAX Versatility on the BD MAX™ System with open system and partner assays.

The BD MAX™ Open System Reagents allow you to create your own lab-developed tests or run third party assays to address emerging diagnostic demands and meet local healthcare needs. BD offers an array of nucleic acid extraction and amplification reagents for use on the BD MAX™ System.

Related Assays

Assays available for BD MAX™ system

Related Family

BD MAX™ performance, efficiency and versatility

MAX PERFORMANCE
Improve patient care with speed and accuracy*

  • Reduce time to result and improve sensitivity*13,14,20
  • Support appropriate treatment decisions and infection control13,14,20, 27
  • Improve patient management and resource utilization*13,14,20, 27

MAX EFFICIENCY  
Improve your laboratory’s productivity with a streamlined and standardized workflow

  • Unique assay design provides time savings for your laboratory staff with less than 1.5 minutes hands on time per sample*,42
  • With an average turn around time of approximately 3 hours and the ability to interleave runs, the BD MAX™ System runs up to 96 samples in an 8-hour shift40
  • Room-temperature stable reagents enable convenient inventory management while reducing setup time

MAX VERSATILITY
Improve your laboratory with clinically relevant and differentiated menu offerings

  • Choose from a broad and clinically relevant suite of 13 molecular IVD or EUA assays
  •  Mix and match assays on the same run to support your laboratory’s testing needs
  • Address emerging diagnostic demands by utilizing the BD MAX™ System Open System Reagents to create your own lab developed tests or run third party assays

*As compared to traditional methods

Get in touch with a sales representative 

  1.   BD MAXTM System User’s Manual. Becton, Dickinson, and Company: Sparks, MD
  2.   Mortensen JE et al. BMC Clin Pathol. 2015;15:9.
  3.   Madison-Antenucci S et al. J Clin Microbiol. 2016;54(11):2681-8.
  4.   Scallan E at al. Emerg Infect Dis. 2011;17(1):7-15.
  5.   Bresee JS, Marcus R, Venezia RA, et al. The etiology of severe acute gastroenteritis among adults visiting emergency departments in the United States. J Infect Dis 2012;205(9):1374–81.
  6.   CDC 2016. https://www.cdc.gov/foodborneburden/2011-foodborne-estimates.html. Page last reviewed: April 24, 2023.
  7.   Humphries RM, Linscott AJ. Laboratory diagnosis of bacterial gastroenteritis. Clinical Microbiology Reviews. 2015 Jan;28(1):3-31.
  8.   Mortensen et al. BMC Clinical Pathology (2015) 15:9 DOI 10.1196/s12907-015-0010-8
  9.   Anderson N. Buchan B. Ledoboer N. “Comparison of the BD MAX Enteric Bacterial Panel to Routine Culture Methods for Detection of Camplyobacter, Enterohemorrhagic Escherichia coli (O157), Salmonella, and Shigella Isolates in Preserved Stool Specimens”, Journal of Clinical Microbiology. 2014 Apr; 52(4): 1222-1224.
  10.   CDC. https://www.cdc.gov/dpdx/amebiasis/index.html. Accessed June 9, 2022.
  11.   CDC. https://www.cdc.gov/norovirus/lab/diagnosis.html. Accessed May 15, 2023.
  12.   Mortensen JE et al. BMC Clin Pathol. 2015;15:9
  13.   Mortensen J E, Ventrola C, Hanna S, & Walter A. Comparison of time-motion analysis of conventional stool culture and the BD MAX™ Enteric Bacterial Panel (EBP). BMC Clinical Pathology. 2015;15(9):1-6
  14.   Ferrer J. et al. BD MAXTM enteric bacterial, bacterial plus, and virus panels for diagnosis of acute infectious gastroenteritis: a cost-benefit analysis. Microbiology Spectrum. 2022;10(5
  15.   Mortensen J E, Ventrola C, Hanna S, & Walter A. Comparison of time-motion analysis of conventional stool culture and the BD MAX™ Enteric Bacterial Panel (EBP). BMC Clinical Pathology. 2015;15(9):1-6
  16.   BD MAXTM Extended Enteric Bacterial Panel Package Insert.
  17.   BD MAXTM Enteric Parasite Panel Package Insert
  18.   BD MAXTM Enteric Viral Panel Package Insert
  19.   Healthcare-Associated Infections (HAIs) | Agency for Healthcare Research and Quality (ahrq.gov)
  20.   Bode LG, et al. Preventing Surgical Site Infections in Nasal Carriers of Staphlococcus aureus. New England Journal of Medicine. 2010;362(1):9-17
  21.   Deburger, B.A., & Mortensen, J.E. One Laboratory’s Experience with the Transition from Culture to Molecular Methods for the Detection of Methicillin-Susceptiple Staphlococcus aureus and Methicillin-Resistant Staphylococcus aureus. Journal of Continuing Education Topics & Issues, vol. 20, no. 2, 2018. P.34+
  22.   45(8):2486-2490.
  23.   BD MAXTM Cdiff Package Insert
  24.   BD MAXTM StaphSR Package Insert
  25.   BD MAXTM CPO Package Insert
  26.   https://www.cdc.gov/nchhstp/newsroom/fact-sheets/std/STI-Incidence-Prevalence-Cost-Factsheet.html Accessed Feb 7, 2024
  27.   Hillier SL et al. Clin Infect Dis. 2021;72(9):1538–43. 2. Ryan-Wenger NA et al. Nurs Res. 2010;59(1):2–10
  28.   BD MAX™ Vaginal Panel Press Release 2016
  29.   BD MAX™ Vaginal Panel Package Insert 
  30.   BD MAXTM CTGCTV2 Package Insert
  31.   BD MAXTM GBS Package Insert
  32.   CDC. Similarities and Differences between Flu and COVID-19. Updated January 2022. Accessed 27 May 2022. www.cdc.gov/flu/symptoms/flu-vs-covid19.htm
  33.   NFID. Respiratory Syncytial Virus (RSV). Updated February 2022. Accessed 27 May 2022. https://www.nfid.org/infectious-diseases/rsv/.
  34.   Musuuza JS et al. PLoS One. 2021;16(5):e0251170.
  35.   Swets MC et al. Lancet. 2022;399(10334):1463–4.
  36.   BD Respiratory Viral Panel for BD MAXTM System Package Insert
  37.   BD Respiratory Viral Panel for BD MAX™ System Package Insert
  38.    Ali A et al. Int J Infect Dis. 2020;90:170–80
  39.   FID. Respiratory Syncytial Virus (RSV). Updated February 2022. Accessed 27 May 2022. https://www.nfid.org/infectious-diseases/rsv/.
  40.   CDC. CDC’s Diagnostic Multiplex Assay for Flu and COVID-19 at Public Health Laboratories and Supplies. Updated October 2021. Accessed 27 May 2022. https://www.cdc.gov/coronavirus/2019-ncov/lab/multiplex.html
  41.   BD SARS-CoV-2 Reagents for BD MAXTM System Package Insert
  42.   Felder RA et al. J Lab Autom. 2014;19(5):468–73